Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation, demyelination, and neurodegeneration within the central nervous system (CNS). It predominantly affects women and young adults, with environmental and genetic factors contributing to its onset. MS presents a wide range of neurological symptoms due to the scattering of lesions in the CNS, often leading to vision, sensorimotor, and cognitive impairments. The clinical course of MS varies, with relapsing-remitting MS (RRMS) being the most common, followed by secondary progressive MS (SPMS) and primary progressive MS (PPMS). Diagnosis is based on clinical evaluation, MRI findings, and cerebrospinal fluid analysis, with the McDonald criteria playing a key role in confirming dissemination in time and space. Current treatments, such as disease-modifying therapies (DMTs) and steroids, focus on managing relapses and reducing long-term disability. Novel therapies, including remyelination and neuroprotective agents, are showing promise in advancing care. While these medications can slow progression and improve quality of life, MS remains an incurable disease that requires ongoing research to find more effective therapies. Surgical interventions are rare but can address severe symptoms like spasticity and bladder dysfunction, contributing to an overall personalized management approach.
Citation: Arosh S. Perera Molligoda Arachchige, Jad El Choueiri, Francesca Pellicanò, Francesco Laurelli, Gabriel Amorim Moreira Alves, Niccolò Stomeo. A review of multiple sclerosis: From pathophysiology to latest therapeutic advances[J]. AIMS Neuroscience, 2025, 12(4): 514-538. doi: 10.3934/Neuroscience.2025026
Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation, demyelination, and neurodegeneration within the central nervous system (CNS). It predominantly affects women and young adults, with environmental and genetic factors contributing to its onset. MS presents a wide range of neurological symptoms due to the scattering of lesions in the CNS, often leading to vision, sensorimotor, and cognitive impairments. The clinical course of MS varies, with relapsing-remitting MS (RRMS) being the most common, followed by secondary progressive MS (SPMS) and primary progressive MS (PPMS). Diagnosis is based on clinical evaluation, MRI findings, and cerebrospinal fluid analysis, with the McDonald criteria playing a key role in confirming dissemination in time and space. Current treatments, such as disease-modifying therapies (DMTs) and steroids, focus on managing relapses and reducing long-term disability. Novel therapies, including remyelination and neuroprotective agents, are showing promise in advancing care. While these medications can slow progression and improve quality of life, MS remains an incurable disease that requires ongoing research to find more effective therapies. Surgical interventions are rare but can address severe symptoms like spasticity and bladder dysfunction, contributing to an overall personalized management approach.
| [1] | Filippi M, Rocca MA (2020) Multiple Sclerosis. White Matter Diseases . Cham: Springer. https://doi.org/10.1007/978-3-030-38621-4_1 |
| [2] | Filippi M, Bar-Or A, Piehl F, et al. (2018) Multiple sclerosis. Nat Rev Dis Primers 4: 43. https://doi.org/10.1038/s41572-018-0041-4 |
| [3] | Li J, Zhang L, Chu Y, et al. (2016) Astrocytes in Oligodendrocyte Lineage Development and White Matter Pathology. Front Cell Neurosci 10: 119. https://doi.org/10.3389/fncel.2016.00119 |
| [4] | Wegner C (2013) Recent insights into the pathology of multiple sclerosis and neuromyelitis optica. Clin Neurol Neurosurg 115 Suppl 1: S38-41. https://doi.org/10.1016/j.clineuro.2013.09.019 |
| [5] | Harbo HF, Gold R, Tintoré M (2013) Sex and gender issues in multiple sclerosis. Ther Adv Neurol Disord 6: 237-248. https://doi.org/10.1177/1756285613488434 |
| [6] | Pena JA, Lotze TE (2013) Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis 2013: 673947. https://doi.org/10.1155/2013/673947 |
| [7] | Naseri A, Nasiri E, Sahraian MA, et al. (2021) Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis. Mult Scler Relat Disord 50: 102816. https://doi.org/10.1016/j.msard.2021.102816 |
| [8] | Ponzio M, Tacchino A, Amicizia D, et al. (2022) Prevalence of multiple sclerosis in Liguria region, Italy: an estimate using the capture-recapture method. Neurol Sci 43: 3239-3245. https://doi.org/10.1007/s10072-021-05718-w |
| [9] | Italian Multiple Sclerosis Register. [cited 2024 October 09]. Available from: https://registroitalianosm.it/en/#:~:text=To%20date%2C%20in%20Italy%20every,people%20living%20with%20the%20disease |
| [10] | Patsopoulos NA (2018) Genetics of Multiple Sclerosis: An Overview and New Directions. Cold Spring Harb Perspect Med 8: a028951. https://doi.org/10.1101/cshperspect.a028951 |
| [11] | Simpson S, Taylor BV, van der Mei I (2015) The role of epidemiology in MS research: Past successes, current challenges and future potential. Mult Scler 21: 969-977. https://doi.org/10.1177/1352458515574896 |
| [12] | Bjørnevik K, Riise T, Casetta I, et al. (2014) Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Mult Scler 20: 1042-1049. https://doi.org/10.1177/1352458513513968 |
| [13] | Daryabor G, Gholijani N, Kahmini FR (2023) A review of the critical role of vitamin D axis on the immune system. Exp Mol Pathol 132–133: 104866. https://doi.org/10.1016/j.yexmp.2023.104866 |
| [14] | Karni A, Kahana E, Zilber N, et al. (2003) The frequency of multiple sclerosis in jewish and arab populations in greater jerusalem. Neuroepidemiology 22: 82-86. https://doi.org/10.1159/000067101 |
| [15] | Riise T, Mohr DC, Munger KL, et al. (2011) Stress and the risk of multiple sclerosis. Neurology 76: 1866-1871. https://doi.org/10.1212/WNL.0b013e31821d74c5 |
| [16] | Mohr DC, Hart SL, Julian L, et al. (2004) Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 328: 731. https://doi.org/10.1136/bmj.38041.724421.55 |
| [17] | Hedström AK (2023) Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection. Front Immunol 14: 1212676. https://doi.org/10.3389/fimmu.2023.1212676 |
| [18] | Finsterer J (2022) Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates. Int J Mol Sci 23: 14222. https://doi.org/10.3390/ijms232214222 |
| [19] | Jokubaitis VG, Campagna MP, Ibrahim O, et al. (2023) Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity. Brain 146: 2316-2331. https://doi.org/10.1093/brain/awac449 |
| [20] | Barcellos LF, Oksenberg JR, Begovich AB, et al. (2003) HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 72: 710-716. https://doi.org/10.1086/367781 |
| [21] | van Langelaar J, Rijvers L, Smolders J, et al. (2020) B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers. Front Immunol 11: 760. https://doi.org/10.3389/fimmu.2020.00760 |
| [22] | Barkhof F, Koeller KK (2020) Demyelinating Diseases of the CNS (Brain and Spine). Diseases of the Brain, Head and Neck, Spine 2020–2023 . Cham: IDKD Springer Series, Springer. https://doi.org/10.1007/978-3-030-38490-6_13 |
| [23] | Yang Y, Wang M, Xu L, et al. (2022) Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review. Front Neurol 13: 874388. https://doi.org/10.3389/fneur.2022.874388 |
| [24] | Casini G, Yurashevich M, Vanga R, et al. (2013) Are Periventricular Lesions Specific for Multiple Sclerosis?. J Neurol Neurophysiol 4: 150. https://doi.org/10.4172/2155-9562.1000150 |
| [25] | Joy JE, Johnston RB (2001) Institute of Medicine (US) Committee on Multiple Sclerosis: Current Status and Strategies for the FutureMultiple Sclerosis: Current Status and Strategies for the Future. Washington (DC): National Academies Press (US). [cited 2025 October 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK222386/ |
| [26] | Zhang K, Zhao Y, Liang Z, et al. (2020) Validity of the McDonald criteria in predicting second events in multiple sclerosis. Mult Scler Relat Disord 43: 102223. https://doi.org/10.1016/j.msard.2020.102223 |
| [27] | Klineova S, Lublin FD (2018) Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med 8: a028928. https://doi.org/10.1101/cshperspect.a028928 |
| [28] | Sundaram AN, Gelkopf MJ (2022) Abducens Nerve Palsy as a Presenting Symptom of Multiple Sclerosis. Turk J Ophthalmol 52: 291-294. https://doi.org/10.4274/tjo.galenos.2022.13245 |
| [29] | Halilovic EA, Alimanovic I, Suljic E, et al. (2014) Optic neuritis as first clinical manifestations the multiple sclerosis. Mater Sociomed 26: 246-248. https://doi.org/10.5455/msm.2014.246-2481 |
| [30] | Nij Bijvank JA, van Rijn LJ, Balk LJ, et al. (2019) Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia. Neurology 92: e2299-e2308. https://doi.org/10.1212/WNL.0000000000007499 |
| [31] | Wilkins A (2017) Cerebellar Dysfunction in Multiple Sclerosis. Front Neurol 8: 312. https://doi.org/10.3389/fneur.2017.00312 |
| [32] | Khare S, Seth D (2015) Lhermitte's Sign: The Current Status. Ann Indian Acad Neurol 18: 154-156. https://doi.org/10.4103/0972-2327.150622 |
| [33] | Tafti D, Ehsan M, Xixis KL (2024) Multiple Sclerosis. StatPearls [Internet] . Treasure Island (FL): StatPearls Publishing. [cited 2025 October 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499849/ |
| [34] | Lublin FD, Reingold SC, Cohen JA, et al. (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83: 278-286. https://doi.org/10.1212/WNL.0000000000000560 |
| [35] | Efendi H (2015) Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management. Noro Psikiyatr Ars 52: S1-S11. https://doi.org/10.5152/npa.2015.12608 |
| [36] | Pirko I, Noseworthy JH (2009) Demyelinating Disorders of the Central Nervous System. Textbook of Clinical Neurology : 1103-1133. https://doi.org/10.1016/B978-141603618-0.10048-7 |
| [37] | Lebrun-Frénay C, Okuda DT, Siva A, et al. (2023) The radiologically isolated syndrome: revised diagnostic criteria. Brain 146: 3431-3443. https://doi.org/10.1093/brain/awad073 |
| [38] | Perrone V, Veronesi C, Giacomini E, et al. (2022) The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis. Clin Epidemiol 14: 1327-1337. https://doi.org/10.2147/CLEP.S376005 |
| [39] | Ziemssen T, Bhan V, Chataway J, et al. (2022) Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm 10: e200064. https://doi.org/10.1212/NXI.0000000000200064 |
| [40] | Holland NJ, Schneider DM, Rapp R, et al. (2011) Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community. Int J MS Care 13: 65-74. https://doi.org/10.7224/1537-2073-13.2.65 |
| [41] | Carlson AK, Amin M, Cohen JA (2024) Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. Drugs 84: 285-304. https://doi.org/10.1007/s40265-024-02011-w |
| [42] | Haki M, Al-Biati HA, Al-Tameemi ZS, et al. (2024) Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore) 103: e37297. https://doi.org/10.1097/MD.0000000000037297 |
| [43] | Dugue A (2025) The 2024 Revised McDonald Criteria: AAN 2025 Highlights. Neurology 2: 26-29. https://doi.org/10.33590/neurolamj/ZSFM1010 |
| [44] | Thompson AJ, Banwell BL, Barkhof F, et al. (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17: 162-173. https://doi.org/10.1016/S1474-4422(17)30470-2 |
| [45] | Wattjes MP, Ciccarelli O, Reich DS, et al. (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20: 653-670. https://doi.org/10.1016/S1474-4422(21)00095-8 |
| [46] | Krzyżak AT, Lasek J, Schneider Z, et al. (2024) Diffusion tensor imaging metrics as natural markers of multiple sclerosis-induced brain disorders with a low Expanded Disability Status Scale score. Neuroimage 290: 120567. https://doi.org/10.1016/j.neuroimage.2024.120567 |
| [47] | Krzyzak AT, Lasek J, Slowik A (2025) Diagnostic performance of a multi-shell DTI protocol and its subsets with B-matrix spatial distribution correction in differentiating early multiple sclerosis patients from healthy controls. Front Neurol 16: 1618582. https://doi.org/10.3389/fneur.2025.1618582 |
| [48] | Mazur-Rosmus W, Krzyżak AT (2024) The effect of elimination of gibbs ringing, noise and systematic errors on the DTI metrics and tractography in a rat brain. Sci Rep 14: 15010. https://doi.org/10.1038/s41598-024-66076-z |
| [49] | Lopez-Soley E, Martinez-Heras E, Solana E, et al. (2023) Diffusion tensor imaging metrics associated with future disability in multiple sclerosis. Sci Rep 13: 3565. https://doi.org/10.1038/s41598-023-30502-5 |
| [50] | Nistri R, Ianniello A, Pozzilli V, et al. (2024) Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis. Diagnostics (Basel) 14: 1120. https://doi.org/10.3390/diagnostics14111120 |
| [51] | Deisenhammer F, Zetterberg H, Fitzner B, et al. (2019) The Cerebrospinal Fluid in Multiple Sclerosis. Front Immunol 10: 726. https://doi.org/10.3389/fimmu.2019.00726 |
| [52] | Graner M, Pointon T, Manton S, et al. (2020) Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. PLoS One 15: e0228883. https://doi.org/10.1371/journal.pone.0228883 |
| [53] | Coll-Martinez C, Quintana E, Salavedra-Pont J, et al. (2021) Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis. Brain Behav 11: e2405. https://doi.org/10.1002/brb3.2405 |
| [54] | Gronseth GS, Ashman EJ (2000) Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54: 1720-1725. https://doi.org/10.1212/wnl.54.9.1720 |
| [55] | Leocani L, Guerrieri S, Comi G (2018) Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis. J Neuroophthalmol 38: 350-357. https://doi.org/10.1097/WNO.0000000000000704 |
| [56] | Chiappa KH, Harrison JL, Brooks EB, et al. (1980) Brainstem auditory evoked responses in 200 patients with multiple sclerosis. Ann Neurol 7: 135-143. https://doi.org/10.1002/ana.410070208 |
| [57] | Gobbelé R, Waberski TD, Dieckhöfer A, et al. (2003) Patterns of disturbed impulse propagation in multiple sclerosis identified by low and high frequency somatosensory evoked potential components. J Clin Neurophysiol 20: 283-290. https://doi.org/10.1097/00004691-200307000-00008 |
| [58] | Andelova M, Vodehnalova K, Krasensky J, et al. (2022) Brainstem lesions are associated with diffuse spinal cord involvement in early multiple sclerosis. BMC Neurol 22: 270. https://doi.org/10.1186/s12883-022-02778-z |
| [59] | Higuera L, Carlin CS, Anderson S (2016) Adherence to Disease-Modifying Therapies for Multiple Sclerosis. J Manag Care Spec Pharm 22: 1394-1401. https://doi.org/10.18553/jmcp.2016.22.12.1394 |
| [60] | Gold R, Wolinsky JS, Amato MP, et al. (2010) Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord 3: 351-367. https://doi.org/10.1177/1756285610385608 |
| [61] | Kulu U, Tiftikcioğlu Bİ, Zorlu Y, et al. (2017) Efficacy of Different Durations of Intravenous Methylprednisolone Treatment in Relapses of Multiple Sclerosis. Noro Psikiyatr Ars 54: 57-61. https://doi.org/10.5152/npa.2016.12382 |
| [62] | McGraw CA, Lublin FD (2013) Interferon beta and glatiramer acetate therapy. Neurotherapeutics 10: 2-18. https://doi.org/10.1007/s13311-012-0163-4 |
| [63] | Fragoso YD (2014) Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Expert Opin Drug Saf 13: 1743-1748. https://doi.org/10.1517/14740338.2014.955849 |
| [64] | Gajofatto A, Benedetti MD (2015) Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?. World J Clin Cases 3: 545-355. https://doi.org/10.12998/wjcc.v3.i7.545 |
| [65] | Krämer J, Bar-Or A, Turner TJ, et al. (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol 19: 289-304. https://doi.org/10.1038/s41582-023-00800-7 |
| [66] | Simpson A, Mowry EM, Newsome SD (2021) Early Aggressive Treatment Approaches for Multiple Sclerosis. Curr Treat Options Neurol 23: 19. https://doi.org/10.1007/s11940-021-00677-1 |
| [67] | Lin M, Zhang J, Zhang Y, et al. (2022) Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev 5: CD013247. https://doi.org/10.1002/14651858.CD013247.pub2 |
| [68] | Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. (2024) Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 1: CD011381. https://doi.org/10.1002/14651858.CD011381.pub3 |
| [69] | Agrawal A, Srivastava MVP, Bhatia R, et al. (2023) A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis-A Prospective Cohort Study. Brain Sci 13: 1249. https://doi.org/10.3390/brainsci13091249 |
| [70] | Rafiee Zadeh A, Ghadimi K, Ataei A, et al. (2019) Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. Int J Physiol Pathophysiol Pharmacol 11: 105-114. |
| [71] | de Sa JC, Airas L, Bartholome E, et al. (2011) Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord 4: 139-168. https://doi.org/10.1177/1756285611403646 |
| [72] | Izquierdo G (2017) Multiple sclerosis symptoms and spasticity management: new data. Neurodegener Dis Manag 7: 7-11. https://doi.org/10.2217/nmt-2017-0034 |
| [73] | Nelson MES, McGuire JR (2019) Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction. Neuromodulation 22: 839-842. https://doi.org/10.1111/ner.12974 |
| [74] | Erwin A, Gudesblatt M, Bethoux F, et al. (2011) Intrathecal baclofen in multiple sclerosis: too little, too late?. Mult Scler 17: 623-629. https://doi.org/10.1177/1352458510395056 |
| [75] | Vecchio M, Chiaramonte R, DI Benedetto P (2022) Management of bladder dysfunction in multiple sclerosis: a systematic review and meta-analysis of studies regarding bladder rehabilitation. Eur J Phys Rehabil Med 58: 387-396. https://doi.org/10.23736/S1973-9087.22.07217-3 |
| [76] | Phé V, Chartier-Kastler E, Panicker JN (2016) Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol 13: 275-288. https://doi.org/10.1038/nrurol.2016.53 |
| [77] | Çetinel B, Kocjancic E, Demirdağ Ç (2016) Augmentation cystoplasty in neurogenic bladder. Investig Clin Urol 57: 316-323. https://doi.org/10.4111/icu.2016.57.5.316 |
| [78] | Chkir S, Michel F, Akakpo W, et al. (2022) Non-continent Urinary Diversion (Ileal Conduit) as Salvage Therapy in Patients With Refractory Lower Urinary Tract Dysfunctions due to Multiple Sclerosis: Results of a National Cohort From the French Association of Urology (AFU) Neurourology Committee and the French-speaking Neurourology Study Group (GENULF). Urology 168: 216-221. https://doi.org/10.1016/j.urology.2022.06.014 |
| [79] | Makhoul K, Ahdab R, Riachi N, et al. (2020) Tremor in Multiple Sclerosis-An Overview and Future Perspectives. Brain Sci 10: 722. https://doi.org/10.3390/brainsci10100722 |
| [80] | Brandmeir NJ, Murray A, Cheyuo C, et al. (2020) Deep Brain Stimulation for Multiple Sclerosis Tremor: A Meta-Analysis. Neuromodulation 23: 463-468. https://doi.org/10.1111/ner.13063 |
| [81] | Koch M, Mostert J, Heersema D, et al. (2007) Tremor in multiple sclerosis. J Neurol 254: 133-145. https://doi.org/10.1007/s00415-006-0296-7 |
| [82] | Ohshita N, Gamoh S, Kanazumi M, et al. (2017) Anesthetic Management of a Patient With Multiple Sclerosis. Anesth Prog 64: 97-101. https://doi.org/10.2344/anpr-64-02-10 |
| [83] | Dulamea A (2015) Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. J Med Life 8: 24-27. |
| [84] | Cadavid D, Mellion M, Hupperts R, et al. (2019) Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 18: 845-856. https://doi.org/10.1016/S1474-4422(19)30137-1 |
| [85] | Foale S, Berry M, Logan A, et al. (2017) LINGO-1 and AMIGO3, potential therapeutic targets for neurological and dysmyelinating disorders?. Neural Regen Res 12: 1247-1251. https://doi.org/10.4103/1673-5374.213538 |
| [86] | Kalluri HV, Rosebraugh MR, Misko TP, et al. (2023) Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Ann Neurol 93: 285-296. https://doi.org/10.1002/ana.26503 |
| [87] | Nakamura K, Thoomukuntla B, Bena J, et al. (2024) Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis. Mult Scler 30: 369-380. https://doi.org/10.1177/13524585231224702 |
| [88] | Coerver EME, Fung WH, De Beukelaar J, et al. (2025) Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: The DOT-MS randomized clinical trial. JAMA Neurology 82: 123-131. https://doi.org/10.1001/jamaneurol.2024.4164 |
| [89] | Duan H, Jing Y, Li Y, et al. (2023) Rehabilitation treatment of multiple sclerosis. Front Immunol 14: 1168821. https://doi.org/10.3389/fimmu.2023.1168821 |
| [90] | Pourhaji F, Peyman N, Taraghdar MM, et al. (2023) Explaining the burden of psychosocial factors on the worsening symptoms of MS: a qualitative study of patients' experiences. BMC Neurol 23: 98. https://doi.org/10.1186/s12883-023-03148-z |
| [91] | Di Cara M, Grezzo D, Palmeri R, et al. (2022) Psychological well-being in people with multiple sclerosis: a descriptive review of the effects obtained with mindfulness interventions. Neurol Sci 43: 211-217. https://doi.org/10.1007/s10072-021-05686-1 |
| [92] | Butzkueven H, Ponsonby AL, Stein MS, et al. (2024) Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain 147: 1206-1215. https://doi.org/10.1093/brain/awad409 |
| [93] | Wu L, Lu J, Lan T, et al. (2024) Stem cell therapies: a new era in the treatment of multiple sclerosis. Front Neurol 15: 1389697. https://doi.org/10.3389/fneur.2024.1389697 |
Figures(8) / Tables(3)
Arosh S. Perera Molligoda Arachchige, Jad El Choueiri, Francesca Pellicanò, Francesco Laurelli, Gabriel Amorim Moreira Alves, Niccolò Stomeo. A review of multiple sclerosis: From pathophysiology to latest therapeutic advances[J]. AIMS Neuroscience, 2025, 12(4): 514-538. doi: 10.3934/Neuroscience.2025026
DownLoad: